We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Eli Lilly is countering a published report that claims the company’s internal data showed a higher rate of diabetes in patients taking its antipsychotic medication Zyprexa than documented in the information provided to doctors.
Bristol-Myers Squibb (BMS) will pay $499 million to the government and sign a corporate integrity agreement to resolve “several investigations involving the company’s drug pricing and sales and marketing activities,” the company said.
Sanofi pasteur has completed production of more than 170 million doses of influenza vaccine, making it the largest contributor to this year’s global supply, the company said.
Moving to cut in on the proposed merger between CVS and Caremark Rx, Express Scripts is proposing to acquire all of the remaining shares of Caremark for about $26 billion, the company announced.
Eli Lilly is denying assertions in two articles in TheNew York Times that claim the company’s own internal documents show that it sought to downplay increased diabetes risk from Zyprexa, its best-selling antipsychotic drug.
Novo Nordisk will increase its diabetes sales force by 700 in an attempt to strengthen its hold on the U.S. insulin market, the firm announced. Read More
Representing small and mid-sized device and diagnostics firms, the Medical Device Manufacturers Association (MDMA) in 2007 will lobby Congress to support reduced FDA user fees, expand small business provisions for MDMA members, reconsider Medicare gainsharing policies and repeal the Medicare anti-kickback safe harbor for hospital group purchasing organizations (GPOs), its top official said in a recent interview. Read More